MAPT and Alzheimer disease: Consequently, several AD diagnostic criteria recommend the use of biomarkers tightly associated with AD pathological hallmarks (McKhann et al., 2011; Dubois et al., 2014) in the evaluation of patients with cognitive decline, including quantification of Aβ and p-tau in the cerebrospinal fluid (CSF) (Molinuevo et al., 2018) and positron emission tomography (PET) (Johnson et al., 2012).